Alpha Teknova Set to Prosper from Expected Boom in Cell & Gene Therapies: KeyBanc Analyst

KeyBanc Capital Markets has initiated coverage on Alpha Teknova Inc TKNO with a Sector Weight rating.

Alpha Teknova is a pure play on the reagents and consumables needed in a lab for cell therapy production, synthetic biology, and other processes. 

Teknova's emphasis on ready-to-use products, short lead times, and scale attracts customers.

KeyBanc notes that if Cell & Gene Therapies achieve their potential success, Alpha Teknova will be a significant research technology provider for many programs.

The analyst notes five Cell & Gene Therapies approvals in 2022, with an expected 10-14 approvals or accepted filings by the EU and the FDA in 2023. 

Successful Cell & Gene Therapies approvals and successful TKNO revenue results will increase confidence that TKNO can accelerate revenue growth.

The analyst writes that the company's customers include early-stage biotech, and revenue should only show low-single-digit growth in 2023 due to funding constraints. 

The company is raising capital through an at-the-market program, and the analyst estimates that about $10-$20 million of capital is needed.

The analyst also notes that the completion of the company's Hollister, CA, facility and $200 million in revenue is possible, but the utilization rate is uncertain.

Price Action: TKNO shares are up 5.92% at $3.04 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsPenny StocksHealth CareInitiationAnalyst RatingsTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!